Rerouting DOT1L inhibitors in leukemia

Blood. 2020 Oct 22;136(17):1900-1901. doi: 10.1182/blood.2020007352.
No abstract available

Publication types

  • Comment

MeSH terms

  • Gray Platelet Syndrome*
  • Histone-Lysine N-Methyltransferase / genetics
  • Humans
  • Leukemia* / drug therapy
  • Myeloid-Lymphoid Leukemia Protein

Substances

  • Myeloid-Lymphoid Leukemia Protein
  • DOT1L protein, human
  • Histone-Lysine N-Methyltransferase